A Comprehensive Monograph on Dexamethasone Acetate: Chemistry, Pharmacology, Clinical Utility, and Regulatory Profile

Section 1: Identification and Chemical Profile

Dexamethasone acetate is a synthetic glucocorticoid, a corticosteroid ester that belongs to the class of small molecule drugs.[1] Developed in 1957, it is a derivative of the parent compound dexamethasone, which is structurally analogous to endogenous corticosteroids such as hydrocortisone and prednisolone.[1] As a potent anti-inflammatory and immunosuppressive agent, dexamethasone acetate has been utilized in the management of a wide spectrum of inflammatory, allergic, and autoimmune conditions.[1] While it has been largely superseded in some applications by the more water-soluble dexamethasone phosphate, the acetate form continues to hold relevance, particularly in formulations designed for sustained local or systemic effects.[1] Its unique physicochemical properties, stemming from the C21 acetate ester, are central to its formulation characteristics and pharmacokinetic profile.

1.1. Nomenclature and Identifiers

The precise identification of a pharmaceutical substance is paramount for clinical safety, research accuracy, and regulatory clarity. Dexamethasone acetate is cataloged under numerous systematic names, synonyms, and registry numbers across various chemical and medical databases. The extensive list of synonyms can create potential for confusion, underscoring the importance of relying on standardized identifiers such as the CAS Number and DrugBank Accession Number for unambiguous reference. For instance, its close structural relationship with betamethasone, a stereoisomer, means it is sometimes referenced as an impurity in betamethasone acetate preparations.[5] A consolidated list of its primary identifiers is provided in Table 1.

Table 1: Key Identifiers and Synonyms for Dexamethasone Acetate

Identifier Type	Value	Source(s)
Primary Name	Dexamethasone acetate	1
Systematic (IUPAC) Name	phenanthren-17-yl]-2-oxoethyl] acetate	3
CAS Number	1177-87-3	1
DrugBank ID	DB14649	1
PubChem CID	236702	2
UNII (FDA GSRS)	K7V8P532WP	2
European Community (EC) Number	214-646-8	3
Common Synonyms	Dexamethasone 21-acetate; 16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate; 9alpha-Fluoro-16alpha-methylprednisolone acetate; Prednisolone F acetate	1
Select Trade Names	Decadronal; Decadron-LA; Panasone; Fortecortin	3
Pharmacopeial Reference	Betamethasone Acetate Impurity B (EP)	5

1.2. Physicochemical Properties

The therapeutic behavior of dexamethasone acetate is intrinsically linked to its chemical structure and physical properties. These characteristics dictate its solubility, stability, formulation possibilities, and interaction with biological systems.

• Molecular Formula and Weight: The chemical formula for dexamethasone acetate is C24​H31​FO6​.[1] It has an average molecular weight of approximately 434.5 g/mol and a monoisotopic mass of 434.210467 Da.[1]
• Chemical Structure: As a synthetic pregnane corticosteroid, its structure features a fluorinated steroid nucleus with an acetate group esterified at the C21 position. Standardized representations include:
• SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C [3]
• InChIKey: AKUJBENLRBOFTD-RPRRAYFGSA-N [3]
• Physical Appearance: It is described as a white to off-white, odorless, crystalline powder that is stable in air.[10]
• Solubility Profile: The solubility profile is a critical determinant of its formulation and clinical use. The acetate ester renders the molecule lipophilic and poorly soluble in aqueous media.
• Water: It is classified as practically insoluble in water, with a reported solubility of 13 mg/L at 25 °C.[10]
• Organic Solvents: It is freely soluble in solvents such as acetone and methanol, and soluble in dimethyl sulfoxide (DMSO), ethanol, chloroform, and dioxane.[4]
• Stability and Storage: Dexamethasone acetate is sensitive to light and heat and should be stored in a cool, dark, and well-ventilated place.[4] The solid form is stable for at least four years under appropriate storage conditions.[4]

The deliberate choice of the acetate ester at the C21 position is a key pharmaceutical strategy. This modification significantly reduces the molecule's aqueous solubility compared to its phosphate salt counterpart, which is readily water-soluble and used for intravenous solutions.[15] The poor solubility of the acetate form is leveraged to create injectable suspensions that, when administered intramuscularly or into a joint space, form a drug depot. This depot allows for the slow, sustained release of the active drug over an extended period, providing a longer duration of action.[4] This explains why the branded product was named Decadron-LA (Long-Acting) and why this form is particularly suited for local injections where prolonged anti-inflammatory effect is desired.[3] This direct link between a fundamental physicochemical property and the drug's clinical application profile distinguishes it from other dexamethasone salts.

Section 2: Comprehensive Pharmacological Profile

The pharmacological activity of dexamethasone acetate is mediated by its active moiety, dexamethasone, a highly potent glucocorticoid. The acetate ester is a pro-drug feature that influences its release and duration of action but is hydrolyzed in vivo to yield the active compound. The following sections detail the molecular mechanisms, physiological effects, and pharmacokinetic journey of dexamethasone.

2.1. Mechanism of Action (MOA)

Dexamethasone exerts its profound anti-inflammatory and immunosuppressive effects through multiple genomic and non-genomic pathways, primarily by acting as a potent agonist for the glucocorticoid receptor (GR).[1]

• Genomic Pathway: This is the principal and most well-characterized mechanism, involving the modulation of gene expression.

1. Receptor Binding: As a lipophilic steroid, dexamethasone readily diffuses across the cell membrane and binds with high affinity to the GR (also known as NR3C1), which resides in the cytoplasm in an inactive complex with heat shock proteins.[15]
2. Nuclear Translocation: Upon binding, the receptor undergoes a conformational change, dissociates from the chaperone proteins, and the activated drug-receptor complex translocates into the nucleus.[18]
3. Gene Modulation: Within the nucleus, the complex interacts with specific DNA sequences known as Glucocorticoid Response Elements (GREs) located in the promoter regions of target genes.[18] This interaction can either increase or decrease the rate of gene transcription.

• Transactivation: The complex binds to GREs to upregulate the transcription of genes encoding anti-inflammatory proteins. A key example is Annexin A1 (also called lipocortin), which is a primary target of dexamethasone acetate.[15] Annexin A1 inhibits the enzyme phospholipase A2 (PLA2), thereby blocking the release of arachidonic acid from cell membranes. This action halts the downstream production of potent inflammatory mediators, including prostaglandins, leukotrienes, and thromboxanes.[1]
• Transrepression: The complex suppresses the expression of pro-inflammatory genes. This is achieved either by direct binding to negative GREs or, more commonly, by interfering with the activity of other transcription factors, such as nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1).[3] This transrepression leads to a marked reduction in the synthesis of pro-inflammatory cytokines (e.g., Interleukin-1 (IL-1), IL-2, IL-6, Tumor Necrosis Factor-alpha (TNF-α)), enzymes (e.g., Cyclooxygenase-2 (COX-2), inducible Nitric Oxide Synthase (iNOS)), and cell adhesion molecules.[15]
• Non-Genomic Pathway: Dexamethasone also mediates rapid effects that are independent of gene transcription and protein synthesis. These actions occur within minutes and are thought to be initiated by interactions with membrane-bound GRs or through direct physicochemical effects on cellular membranes.[15] These non-genomic effects include the stabilization of lysosomal membranes, which prevents the release of destructive enzymes, and the rapid inhibition of T-cell receptor signaling pathways.[1]

2.2. Pharmacodynamics

The pharmacodynamic profile of dexamethasone is characterized by high glucocorticoid potency, minimal mineralocorticoid activity, and significant metabolic and endocrine effects.

• Anti-inflammatory and Immunosuppressive Potency: Dexamethasone is one of the most potent synthetic corticosteroids. The presence of a fluorine atom at the 9-alpha position and a methyl group at the 16-alpha position greatly enhances its glucocorticoid activity. It is approximately 35 times more potent than endogenous cortisone and 7 times more potent than prednisolone in its anti-inflammatory effects.[15] It effectively suppresses all phases of the inflammatory response by inhibiting the migration and function of immune cells such as neutrophils, macrophages, and lymphocytes.[15]
• Mineralocorticoid Activity: A key clinical advantage of dexamethasone is its negligible mineralocorticoid activity.[3] Unlike hydrocortisone, it does not cause significant sodium and water retention or potassium excretion. This makes it a preferred agent in conditions where fluid retention would be detrimental, such as in the management of cerebral edema.[23]
• Metabolic Effects: Dexamethasone exerts profound and varied effects on carbohydrate, protein, and lipid metabolism. It stimulates gluconeogenesis and glycogenolysis in the liver while decreasing peripheral glucose uptake, which can lead to hyperglycemia and may unmask latent diabetes or worsen glycemic control in known diabetics.[23] It also promotes protein catabolism, which can result in muscle wasting, and alters fat distribution, leading to the characteristic Cushingoid features (e.g., truncal obesity, "moon face") with chronic use.[23]
• Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: The high potency of dexamethasone leads to potent negative feedback on the HPA axis, suppressing the release of corticotropin-releasing hormone (CRH) from the hypothalamus and adrenocorticotropic hormone (ACTH) from the pituitary gland. This results in decreased endogenous cortisol production by the adrenal glands.[20] This effect is both dose- and duration-dependent and is the basis for its use in the diagnostic suppression test for Cushing's syndrome. However, it also represents a significant clinical liability, as prolonged use leads to adrenal atrophy and insufficiency, requiring a gradual tapering of the dose upon discontinuation to allow the HPA axis to recover.[17]

2.3. Pharmacokinetics (ADME)

The pharmacokinetics of dexamethasone acetate are primarily governed by the properties of the active dexamethasone moiety following hydrolysis of the ester.

• Absorption: Dexamethasone is well-absorbed after oral administration, with a high bioavailability of approximately 80%.[15] Peak plasma concentrations are typically reached within 1 to 2 hours.[22] When administered as an intramuscular injection of the acetate suspension, absorption is slower and more prolonged, creating the sustained-release profile characteristic of this formulation.[4]
• Distribution: Dexamethasone is extensively distributed throughout the body tissues.[27] In plasma, it is approximately 60–77% bound to proteins, mainly transcortin and albumin.[15] It has a moderate volume of distribution (e.g., 123 L/70 kg in pediatric patients) and partitions most extensively into the liver.[19] Despite being moderately lipophilic, its distribution into adipose tissue is limited, and brain concentrations are kept low by the action of the P-glycoprotein (P-gp) efflux transporter at the blood-brain barrier.[19]
• Metabolism: Dexamethasone undergoes hepatic metabolism, primarily mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme, with minor contributions from CYP3A5.[18] This metabolic pathway is central to its clinical profile for two reasons. First, its clearance is highly susceptible to interactions with drugs that inhibit or induce CYP3A4. Second, dexamethasone itself is a potent inducer of CYP3A4.[18] This bidirectional relationship means that not only can other drugs alter dexamethasone levels, but dexamethasone can significantly alter the metabolism and clearance of a wide range of co-administered medications that are CYP3A4 substrates. This explains the extensive list of drug-drug interactions associated with dexamethasone and is a critical consideration in clinical practice, particularly in patients on complex medication regimens.
• Excretion: The metabolites of dexamethasone, along with a small amount of unchanged drug (less than 10%), are primarily excreted in the urine.[22] The mean terminal elimination half-life of dexamethasone is approximately 3 to 5 hours.[15] In a veterinary study, elimination was rapid, with 98% of the dose cleared via urine and feces within three days.[29]

Section 3: Clinical Applications and Therapeutic Use

Dexamethasone acetate, and the broader family of dexamethasone formulations, are mainstays in modern medicine due to their potent and broad-spectrum anti-inflammatory and immunosuppressive properties. Their clinical utility spans a vast range of medical specialties, from emergency medicine and critical care to oncology and ophthalmology.

3.1. Approved and Off-Label Indications

Dexamethasone is indicated for the treatment of numerous conditions characterized by inflammatory or aberrant immune responses.

• Inflammatory and Autoimmune Disorders: It is a first-line or adjunctive therapy for rheumatic disorders such as rheumatoid arthritis, psoriatic arthritis, and acute gouty arthritis. It is also used to manage acute exacerbations of multiple sclerosis and systemic autoimmune diseases like systemic lupus erythematosus and dermatomyositis.[6]
• Allergic Conditions: It is used to control severe or incapacitating allergic states that are unresponsive to conventional treatment, including bronchial asthma, atopic and contact dermatitis, and severe drug hypersensitivity reactions.[12]
• Neoplastic Diseases: Dexamethasone is a cornerstone of many chemotherapy regimens. It is used for its direct anti-cancer effects (e.g., inducing apoptosis in lymphoid cells) and for palliative management in leukemias and lymphomas.[12] It is a standard component of combination therapy for multiple myeloma.[6]
• Cerebral Edema: It is a primary treatment for reducing vasogenic cerebral edema associated with primary or metastatic brain tumors, as well as edema following neurosurgery or head injury.[22] Its lack of mineralocorticoid activity makes it particularly suitable for this indication.
• Ophthalmic Diseases: Topical formulations are used for a variety of inflammatory eye conditions, including uveitis, keratitis, and allergic conjunctivitis.[4] Advanced, long-acting intravitreal implants (e.g., Ozurdex) are approved for treating macular edema secondary to retinal vein occlusion or diabetes, and for non-infectious posterior uveitis.[6]
• COVID-19: Following the landmark RECOVERY trial, dexamethasone became a standard of care for hospitalized patients with severe COVID-19 who require supplemental oxygen or mechanical ventilation. It is not recommended for patients with mild to moderate illness who do not require respiratory support.[1]
• Pediatric Applications: In children, it is commonly used as a single-dose treatment for croup to reduce airway swelling and for managing acute asthma exacerbations.[38]
• Diagnostic Use: The dexamethasone suppression test is a standard endocrinological tool used to help diagnose Cushing's syndrome by assessing the integrity of the HPA axis feedback mechanism.[10]
• Other Indications: The drug is also used for various dermatologic diseases (e.g., pemphigus), hematologic disorders (e.g., idiopathic thrombocytopenic purpura), and to promote fetal lung maturation in pregnant women at risk of premature delivery.[4]

3.2. Formulations and Routes of Administration

The versatility of dexamethasone is reflected in the wide array of available formulations, which allow for systemic, local, and topical administration tailored to the specific clinical need.

• Oral: Available as tablets in a wide range of strengths (0.5 mg to 20 mg), as well as an oral elixir and a concentrated solution (Intensol) for ease of administration and dose titration.[22]
• Injectable:
• Dexamethasone Sodium Phosphate: This water-soluble salt is formulated as a clear solution for rapid systemic effect via intravenous (IV) or intramuscular (IM) injection. It can also be used for local administration into joints (intra-articular), lesions (intralesional), or soft tissues.[16]
• Dexamethasone Acetate: This poorly soluble ester is formulated as a suspension for IM or local injection. Its purpose is to provide a sustained, long-acting depot effect, releasing the drug slowly over time.[4]
• Ophthalmic: Formulations for the eye include solutions, suspensions, ointments, and advanced sustained-release devices such as intravitreal implants (Ozurdex) and intracanalicular inserts (Dextenza).[6]
• Topical and Other Routes: Dexamethasone is also available in topical creams, nasal sprays, and otic (ear) solutions, often in combination with anti-infective agents.[6]

3.3. Evidence from Clinical Trials

The widespread use of dexamethasone is supported by decades of clinical experience and numerous trials, with recent studies continuing to refine its role and explore new applications.

• RECOVERY Trial (COVID-19): This large, randomized, controlled trial provided definitive evidence for the use of dexamethasone in severe COVID-19. The trial demonstrated that a low dose of 6 mg daily for up to 10 days reduced 28-day mortality by one-third in ventilated patients and by one-fifth in patients receiving oxygen alone.[37] This finding represented a major breakthrough in the management of the pandemic, showcasing the successful repurposing of an established, inexpensive drug. The mechanism of benefit is directly tied to dexamethasone's ability to quell the hyperinflammatory cytokine storm characteristic of severe disease.[22]
• Oncology Trials: Dexamethasone is a foundational component in the treatment of multiple myeloma and other hematologic malignancies. A multitude of ongoing clinical trials are evaluating its efficacy and safety in combination with newer agents, including proteasome inhibitors (bortezomib), immunomodulatory drugs (lenalidomide), and monoclonal antibodies (daratumumab).[33]
• Advanced Drug Delivery Systems: The therapeutic trajectory of dexamethasone is increasingly focused on innovative delivery systems designed to maximize local efficacy while minimizing systemic side effects. Clinical trials have led to the approval of devices like the Dextenza intracanalicular insert for post-operative ocular pain and the Ozurdex intravitreal implant for macular edema.[36] These technologies solve a primary challenge of corticosteroid therapy: decoupling the potent local anti-inflammatory effects from the problematic systemic adverse events. Preclinical research continues to advance this frontier, with studies exploring novel platforms like drug-eluting nanofibers for corneal injuries and targeted PLGA nanospheres for inflammatory liver diseases.[48]

Table 2: Summary of Dexamethasone Dosage and Administration for Key Indications

Indication	Patient Population	Formulation/Route	Typical Dosage Regimen	Key Clinical Notes	Source(s)
Severe COVID-19	Adult & Adolescent (≥12 years)	Oral / IV	6 mg once daily for up to 10 days.	For hospitalized patients requiring supplemental oxygen or mechanical ventilation only.	34
Cerebral Edema	Adult	IV, then IM/Oral	Initial: 10 mg IV, followed by 4 mg IM every 6 hours.	Dose is tapered down over 5-7 days once symptoms subside.	34
Multiple Myeloma	Adult	Oral	20 mg or 40 mg once daily on specific days of the treatment cycle.	Used in combination with other anti-myeloma agents; regimen-specific.	33
Multiple Sclerosis (Acute Exacerbation)	Adult	Oral	30 mg daily for 1 week, followed by 4-12 mg every other day for 1 month.	High-dose initial therapy followed by a prolonged taper.	34
Croup	Pediatric	Oral / IM	0.6 mg/kg as a single dose (max 16 mg).	A one-time dose is typically sufficient due to the long half-life.	17
Anti-inflammatory	Adult	Oral / IV / IM	Initial: 0.75-9 mg per day, divided q6-12h.	Dosage is highly individualized based on disease severity and patient response.	34
Ophthalmic Inflammation	Adult	Ophthalmic Suspension (0.1%)	1-2 drops in the affected eye(s) every 4-6 hours. For severe disease, may be used hourly initially.	Taper dose as inflammation subsides. Shake suspension well before use.	51

Section 4: Safety, Tolerability, and Risk Management

While dexamethasone is a highly effective medication, its use is associated with a significant and wide-ranging profile of adverse effects, contraindications, and drug interactions. These risks are largely predictable consequences of its potent glucocorticoid activity and are dependent on the dose and duration of therapy. Careful patient selection, monitoring, and risk mitigation strategies are essential for its safe use.

4.1. Adverse Effects Profile

The adverse effects of dexamethasone can impact nearly every organ system. The risk and severity of these effects increase with higher doses and longer treatment duration.

• Endocrine and Metabolic: Chronic use frequently leads to a cushingoid state, characterized by weight gain, central obesity, a "moon face," and fat deposition in the upper back ("buffalo hump").[24] Other common effects include hyperglycemia, which can worsen pre-existing diabetes or induce steroid-induced diabetes, and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency upon withdrawal.[22] Electrolyte disturbances, such as fluid retention and hypokalemia, can also occur.[23]
• Musculoskeletal: Long-term therapy is a major risk factor for osteoporosis and pathologic fractures due to decreased bone formation and increased bone resorption.[24] Patients may also experience steroid-induced myopathy, presenting as proximal muscle weakness, and, less commonly, aseptic necrosis of femoral and humeral heads.[23]
• Gastrointestinal: Dexamethasone can cause dyspepsia and increases the risk of peptic ulceration, gastrointestinal bleeding, and perforation, particularly when used concurrently with nonsteroidal anti-inflammatory drugs (NSAIDs).[23] Pancreatitis has also been reported.[24]
• Immunologic: By suppressing the immune system, dexamethasone increases susceptibility to infections of all types (bacterial, viral, fungal, and parasitic) and can mask the typical signs and symptoms of an ongoing infection.[23] It may also lead to the reactivation of latent infections, such as tuberculosis or hepatitis B.[23]
• Neuropsychiatric: A wide range of psychiatric effects can occur, including insomnia, restlessness, anxiety, euphoria, mood swings, irritability, and, more severely, depression, psychosis, and cognitive impairment (confusion, memory loss).[24]
• Ophthalmic: Prolonged use is associated with the development of posterior subcapsular cataracts and increased intraocular pressure, which can lead to glaucoma and optic nerve damage.[23]
• Cardiovascular: Fluid and sodium retention can lead to or exacerbate hypertension and congestive heart failure in susceptible individuals.[23]
• Dermatologic: Common skin-related side effects include acne, thinning of the skin, easy bruising (ecchymoses), impaired wound healing, and hirsutism (increased hair growth).[26]

4.2. Contraindications and Precautions

The use of dexamethasone is contraindicated in certain situations, and requires careful consideration and monitoring in others.

• Absolute Contraindications:
• Systemic Fungal Infections: Dexamethasone can exacerbate systemic fungal infections and should not be used in their presence unless necessary to control a life-threatening drug reaction.[23]
• Hypersensitivity: Known allergy or hypersensitivity to dexamethasone or any of the formulation's components is a contraindication.[23]
• Live Vaccines: Administration of live or live-attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids due to the risk of disseminated infection.[39]
• Precautions (Use with Caution):
• Infections: Caution is required in patients with active or latent tuberculosis, ocular herpes simplex, or other infections, as the drug can mask symptoms and worsen the condition.[23]
• Cardiovascular and Renal Disease: Use with caution in patients with hypertension, congestive heart failure, recent myocardial infarction, or renal insufficiency due to the risk of fluid retention.[23]
• Gastrointestinal Conditions: Caution is warranted in patients with peptic ulcer disease, diverticulitis, or ulcerative colitis due to the increased risk of perforation.[23]
• Endocrine Disorders: Patients with diabetes mellitus require close blood glucose monitoring. Caution is also advised in patients with hypothyroidism or pheochromocytoma.[33]
• Mental Health Conditions: Patients with a history of psychosis or severe affective disorders may be at higher risk for psychiatric side effects.[26]

4.3. Significant Drug-Drug Interactions

Dexamethasone is involved in numerous clinically significant drug interactions, primarily due to its effects on the CYP3A4 metabolic enzyme. A summary of the most critical interactions is provided in Table 3.

Table 3: Clinically Significant Drug Interactions with Dexamethasone

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Barbiturates, Carbamazepine)	Induction of CYP3A4, which increases the metabolism of dexamethasone.	Decreased plasma concentration and reduced therapeutic efficacy of dexamethasone.	Monitor for reduced efficacy; may require an increased dexamethasone dose.	39
CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin)	Inhibition of CYP3A4, which decreases the metabolism of dexamethasone.	Increased plasma concentration of dexamethasone, leading to a higher risk of adverse effects.	Avoid combination if possible; if necessary, monitor closely for signs of corticosteroid toxicity and consider reducing the dexamethasone dose.	1
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., Ibuprofen, Naproxen, Aspirin)	Pharmacodynamic synergism; both drug classes can cause gastric irritation.	Significantly increased risk of gastrointestinal ulceration, bleeding, and perforation.	Use combination with extreme caution. Consider gastroprotective agents (e.g., PPIs). Monitor for GI symptoms.	1
Antidiabetic Agents (e.g., Metformin, Insulin, Sulfonylureas)	Pharmacodynamic antagonism; dexamethasone causes hyperglycemia.	Decreased efficacy of antidiabetic drugs, leading to poor glycemic control.	Monitor blood glucose levels closely. The dose of the antidiabetic agent may need to be increased.	1
Anticoagulants (e.g., Warfarin, Apixaban, Rivaroxaban)	Mixed: Dexamethasone can induce CYP3A4 (decreasing levels of some DOACs) and has variable effects on warfarin's activity.	Unpredictable changes in anticoagulant effect, leading to increased risk of either thrombosis or bleeding.	Monitor coagulation parameters (e.g., INR for warfarin) very closely. Dose adjustments of the anticoagulant may be necessary.	1
Potassium-Depleting Agents (e.g., Loop/Thiazide Diuretics, Amphotericin B)	Additive pharmacodynamic effect, leading to increased potassium loss.	Increased risk of severe hypokalemia, which can lead to cardiac arrhythmias.	Monitor serum potassium levels closely. Potassium supplementation may be required.	59

Section 5: Use in Special Populations

The therapeutic use of dexamethasone requires specific considerations and adjustments for special patient populations, including children, the elderly, and pregnant or lactating women, to balance efficacy with unique age- and condition-specific risks.

5.1. Pediatric Use

Dexamethasone is widely used in pediatrics for several acute conditions. Its administration in children, particularly for long durations, necessitates careful monitoring.

• Indications: It is a standard treatment for moderate to severe croup, where a single dose effectively reduces airway inflammation and obstruction.[17] It is also used for acute asthma exacerbations, often as a single or two-dose regimen, which may improve compliance and is better tolerated than multi-day courses of prednisolone due to its superior palatability.[40] Additionally, it is an integral component of chemotherapy protocols for pediatric cancers like acute lymphoblastic leukemia (ALL) and lymphomas.[32]
• Dosing: Pediatric dosing is typically calculated based on body weight, with specific regimens for different indications (e.g., 0.6 mg/kg for croup).[34]
• Primary Concern (Growth Suppression): The most significant risk of long-term corticosteroid therapy in children and adolescents is the suppression of linear growth. The drug can interfere with normal bone development and maturation. Therefore, children receiving prolonged treatment must have their height and weight monitored regularly to detect any growth deceleration early.[24]

5.2. Geriatric Use

Elderly patients are often more susceptible to the adverse effects of corticosteroids due to a higher prevalence of comorbidities and age-related physiological changes.

• Increased Risks: The geriatric population is at a heightened risk for corticosteroid-induced side effects, including osteoporosis, hypertension, fluid retention, hyperglycemia, and psychiatric disturbances.[58]
• Dose Optimization: Clinical practice and emerging evidence suggest a need for careful dose optimization in the elderly. For instance, in the treatment of multiple myeloma, studies have shown that discontinuing dexamethasone after the initial treatment phase in intermediate-fit older patients can reduce long-term toxicity without compromising efficacy, leading to better overall outcomes.[62]
• Delirium: While corticosteroids are a known risk factor for delirium in older adults, the relationship can be complex. A retrospective study of older patients hospitalized with COVID-19 found that those treated with dexamethasone had a lower incidence of delirium compared to an untreated cohort.[63] This suggests that in the context of severe systemic inflammation, the anti-inflammatory benefits of the drug may outweigh its direct deliriogenic potential.

5.3. Use in Pregnancy and Lactation

The use of dexamethasone during pregnancy and lactation involves a careful assessment of the benefits to the mother versus the potential risks to the fetus or infant.

• Pregnancy: Dexamethasone readily crosses the placenta. Its primary established use in pregnancy is for promoting fetal lung maturation in women at risk of preterm delivery between 24 and 34 weeks of gestation.[17] This intervention significantly reduces the risk of neonatal respiratory distress syndrome. However, its use for other maternal conditions must be considered cautiously. Systemic corticosteroid use has been associated with potential risks, including a small increase in the risk of orofacial clefts, intrauterine growth restriction, and low birth weight.[22] Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be monitored for signs of hypoadrenalism.[22] The FDA has not assigned a new pregnancy category, but it was historically Category C, while in Australia, oral use is Category A.[39]
• Lactation: Systemically administered dexamethasone is excreted into breast milk, although the amount is likely to be low with standard doses.[65] For short-term use, adverse effects in the infant are unlikely. However, for long-term or high-dose therapy, an alternative corticosteroid with more safety data in lactation, such as prednisolone, may be preferred, especially when nursing a newborn or preterm infant.[67] High systemic doses of corticosteroids have been reported to cause a temporary reduction in milk supply.[66] The use of topical or ophthalmic dexamethasone is considered safe during breastfeeding as systemic absorption is minimal.[68]

5.4. Use in Hepatic and Renal Impairment

• Hepatic Impairment: The metabolism of dexamethasone is primarily hepatic. In patients with cirrhosis, the clearance of corticosteroids is reduced, leading to an enhanced effect and increased risk of side effects. Therefore, it should be used with caution in this population.[23] Specific dose adjustment guidelines are not provided in manufacturer labeling.[22]
• Renal Impairment: The impact of renal impairment on the pharmacokinetics of dexamethasone has not been well-studied. No specific dosage adjustments are recommended in the manufacturer's labeling.[22]

The clinical role and risk-benefit profile of dexamethasone are highly dynamic and context-dependent across a patient's lifespan. In utero, it functions as a developmental promoter for fetal lungs. In childhood, it is a critical tool for acute inflammatory conditions like croup, but its primary risk is developmental suppression. Throughout adulthood, it serves as a powerful and versatile anti-inflammatory agent. Finally, in the geriatric population, the clinical focus shifts to mitigating its cumulative toxicity, often leading to strategies aimed at dose reduction or discontinuation. This highlights that its application must be carefully tailored to the patient's specific life stage and clinical condition.

Section 6: Regulatory Status and Product Information

Dexamethasone acetate, along with other forms of dexamethasone, has a long history of clinical use and is regulated by health authorities worldwide. Its regulatory status, market presence, and branding vary by region.

6.1. Global Regulatory Approvals and History

• United States Food and Drug Administration (FDA): The parent drug, dexamethasone, was first approved by the FDA on October 30, 1958, making it a well-established therapeutic agent.[35] The acetate ester form was specifically approved and marketed as an injectable suspension under the brand name DECADRON-LA (NDA 16-675).[71] In 2002, the manufacturer requested the withdrawal of this product from the market for commercial reasons, not due to concerns about its safety or effectiveness.[71] This FDA determination is significant because it allows for the approval of Abbreviated New Drug Applications (ANDAs) for generic versions of dexamethasone acetate injection.[71] While the branded suspension is discontinued, dexamethasone acetate remains available as a bulk chemical substance for use in animal drug compounding.[72] Numerous other dexamethasone-containing products, utilizing the base drug or the phosphate salt, remain approved and widely marketed in the U.S., including oral tablets (e.g., HEMADY for multiple myeloma) and advanced ophthalmic delivery systems (e.g., Dextenza).[33]
• Australia's Therapeutic Goods Administration (TGA): Dexamethasone products are also regulated by the TGA in Australia. Approved formulations are available for a broad range of indications similar to those in the U.S., including inflammatory, allergic, rheumatic, and neoplastic diseases.[73] Marketed products include dexamethasone phosphate injections (e.g., Dexamethasone Viatris, Dexamethasone Medsurge), oral tablets (e.g., Dexmethsone), and the Ozurdex intravitreal implant for specific ophthalmic conditions like diabetic macular edema.[36]

The regulatory history of dexamethasone acetate illustrates the typical lifecycle of a pharmaceutical formulation. The original branded injectable suspension (DECADRON-LA) has been superseded in mainstream use, likely by more convenient or water-soluble formulations like dexamethasone phosphate for systemic administration. However, the active pharmaceutical ingredient (API) itself remains clinically valuable. Its transition from a widely marketed product to a substance used in more specialized applications, such as compounding, reflects how established APIs can find new niches where their specific properties—in this case, poor solubility and long-acting depot potential—are still therapeutically advantageous.[72]

6.2. International Brand Names

Dexamethasone is marketed globally under a multitude of brand names, and the specific salt form (acetate, phosphate, or base) can vary between products. A selection of brand names from different regions is provided in Table 4.

Table 4: Selected International Brand Names for Dexamethasone Formulations

Region	Brand Name	Formulation	Active Moiety	Source(s)
United States	Decadron-LA (discontinued)	Injectable Suspension	Dexamethasone Acetate	79
	Decadron, Hemady	Tablet	Dexamethasone	6
	Maxidex, Dextenza, Ozurdex	Ophthalmic Suspension/Insert/Implant	Dexamethasone	6
	Dexamethasone Intensol	Oral Solution	Dexamethasone	6
Australia	Dexamethasone Viatris, Dexamethasone Medsurge	Solution for Injection	Dexamethasone Phosphate	75
	Dexmethsone	Tablet	Dexamethasone	77
	Ozurdex	Intravitreal Implant	Dexamethasone	36
United Kingdom	Neofordex, Glensoludex, Martapan	Tablet	Dexamethasone	81
European Union	Neofordex, Ozurdex	Tablet, Implant	Dexamethasone	82
China	Pi Yan Ping	Topical Cream	Dexamethasone Acetate (in combination)	2
Other	Fortecortin	Crystal Suspension	Dexamethasone Acetate	7

Section 7: Conclusion

Dexamethasone acetate (DB14649) is a potent, synthetic glucocorticoid ester with a long and versatile history in clinical medicine. Its identity is well-established through a comprehensive set of chemical and regulatory identifiers, with its defining physicochemical feature being the C21 acetate moiety. This esterification renders the molecule lipophilic and poorly water-soluble, a property that has been strategically utilized to create long-acting depot formulations for intramuscular and local injection, distinguishing it from the rapidly acting, water-soluble phosphate salt.

Pharmacologically, dexamethasone acts as a powerful agonist of the glucocorticoid receptor, modulating gene expression to produce profound anti-inflammatory and immunosuppressive effects. Its high potency and negligible mineralocorticoid activity make it a valuable therapeutic agent, but these same properties are inextricably linked to a broad and significant profile of adverse effects, including HPA axis suppression, metabolic disturbances, and increased susceptibility to infection. Its metabolism via and induction of the CYP3A4 enzyme system is a central factor in its extensive drug-drug interaction profile, demanding careful management in patients on polypharmacy.

Clinically, dexamethasone is a cornerstone therapy for a vast range of inflammatory, autoimmune, allergic, and neoplastic diseases. Its role was dramatically highlighted during the COVID-19 pandemic, where the RECOVERY trial demonstrated its life-saving benefit in patients with severe respiratory complications, a testament to the enduring value of drug repurposing. The future of dexamethasone therapy appears to be moving towards advanced, localized drug delivery systems, such as ophthalmic implants and novel nanoparticle formulations, which aim to maximize therapeutic efficacy at the target site while minimizing systemic toxicity.

The use of dexamethasone must be carefully tailored to specific patient populations, with key considerations for growth suppression in children, heightened risk of toxicity in the elderly, and a nuanced risk-benefit assessment in pregnant and lactating women. In conclusion, Dexamethasone Acetate remains a clinically important molecule, whose utility is defined by its unique pharmacokinetic profile and whose safe and effective use depends on a deep understanding of its potent pharmacology and the comprehensive management of its associated risks.

Works cited

1. Dexamethasone acetate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB14649
2. Dexamethasone acetate - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Dexamethasone_acetate
3. Dexamethasone Acetate | C24H31FO6 | CID 236702 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone-Acetate
4. Dexamethasone Acetate (NSC 39471, CAS Number: 1177-87-3) | Cayman Chemical, accessed September 27, 2025, https://www.caymanchem.com/product/22286/dexamethasone-acetate
5. Dexamethasone Acetate | CAS 1177-87-3 - LGC Standards, accessed September 27, 2025, https://www.lgcstandards.com/PL/en/Dexamethasone-Acetate/p/MM0445.00
6. Dexamethasone - brand name list from Drugs.com, accessed September 27, 2025, https://www.drugs.com/ingredient/dexamethasone.html
7. Dexamethasone acetate | C24H31FO6 - ChemSpider, accessed September 27, 2025, https://www.chemspider.com/Chemical-Structure.206624.html
8. Dexamethasone Acetate - Dexamethasone 21-acetate, 9α-Fluoro-16α-methyl-11β, accessed September 27, 2025, https://www.sigmaaldrich.com/US/en/substance/dexamethasoneacetate434501177873
9. Dexamethasone-21-acetate - the NIST WebBook, accessed September 27, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=1177-87-3
10. Dexamethasone-17-acetate | 1177-87-3 - ChemicalBook, accessed September 27, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9703269.htm
11. Dexamethasone 21-Acetate 1177-87-3 | Tokyo Chemical Industry (India) Pvt. Ltd., accessed September 27, 2025, https://www.tcichemicals.com/IN/en/p/D3628
12. DECADRON® - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011664s064lbl.pdf
13. Dexamethasone Acetate Pharmaceutical Secondary Standard; Certified Reference Material 1177-87-3 - Sigma-Aldrich, accessed September 27, 2025, https://www.sigmaaldrich.com/US/en/product/sial/phr1527
14. DEXAMETHASONE SODIUM PHOSPHATE Label - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040572s002lbl.pdf
15. Dexamethasone Conjugates: Synthetic Approaches and Medical Prospects - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8067246/
16. Dexamethasone Sodium Phosphate Injection, USP - Pfizer, accessed September 27, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=685
17. DEXAMETHASONE injectable - MSF Medical Guidelines, accessed September 27, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/dexamethasone-injectable-16682621.html
18. dexamethasone - ClinPGx, accessed September 27, 2025, https://www.clinpgx.org/chemical/PA449247
19. Physiologically Based Pharmacokinetics of Dexamethasone in Rats - ScienceDirect - DOI, accessed September 27, 2025, https://doi.org/10.1124/dmd.120.091017
20. Pharmacokinetics and pharmacodynamics of dexamethasone after oral administration in apparently healthy horses in - AVMA Journals, accessed September 27, 2025, https://avmajournals.avma.org/view/journals/ajvr/71/7/ajvr.71.7.831.xml
21. Fungal Vaginal Infections | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/indications/DBCOND0071315
22. Dexamethasone - StatPearls - NCBI Bookshelf, accessed September 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482130/
23. DECADRON® - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf
24. Side effects of dexamethasone tablets and liquid - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-tablets-and-liquid/side-effects-of-dexamethasone-tablets-and-liquid/
25. Dexamethasone (Dexamethasone): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 27, 2025, https://www.rxlist.com/dexamethasone-drug.htm
26. Dexamethasone: MedlinePlus Drug Information, accessed September 27, 2025, https://medlineplus.gov/druginfo/meds/a682792.html
27. Dexamethasone Pharmacokinetics - Consensus Academic Search Engine, accessed September 27, 2025, https://consensus.app/questions/dexamethasone-pharmacokinetics/
28. Dose-dependent pharmacokinetics of dexamethasone - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/3709651/
29. Elimination kinetics of dexamethasone in bovine urine, hair and feces following single administration of dexamethasone acetate and phosphate esters - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/47299400_Elimination_kinetics_of_dexamethasone_in_bovine_urine_hair_and_feces_following_single_administration_of_dexamethasone_acetate_and_phosphate_esters
30. Clinical Profile of Dexamethasone Acetate Anhydrous Micronized USP - GlobalRx, accessed September 27, 2025, https://www.globalrx.com/articles?article=dexamethasone-acetate-clinical-profile&product_id=56394
31. dexamethasone acetate - Tahoe Forest Health System, accessed September 27, 2025, https://www.tfhd.com/cancer-center/drug-dictionary/dexamethasone-acetate/
32. Dexamethasone | CCLG - The Children & Young People's Cancer Association, accessed September 27, 2025, https://www.cclg.org.uk/about-cancer/information-resources/publications/dexamethasone
33. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf
34. Decadron, Dexamethasone Intensol (dexamethasone) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 27, 2025, https://reference.medscape.com/drug/decadron-dexamethasone-intensol-dexamethasone-342741
35. Dexamethasone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB01234
36. Australian Public Assessment Report for Dexamethasone - Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/sites/default/files/auspar-ozurdex.pdf
37. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 - RECOVERY Trial, accessed September 27, 2025, https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
38. Dexamethasone acetate monohydrate - TargetMol, accessed September 27, 2025, https://www.targetmol.com/compound/dexamethasone%20acetate
39. Dexamethasone - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Dexamethasone
40. Single-dose dexamethasone for mild-to-moderate asthma exacerbations: Effective, easy, and acceptable - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3192076/
41. How and when to take dexamethasone tablets and liquid - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-tablets-and-liquid/how-and-when-to-take-dexamethasone-tablets-and-liquid/
42. Decadron - Drug Summary, accessed September 27, 2025, https://www.pdr.net/drug-summary/Dexamethasone-Sodium-Phosphate-Injection--USP-4-mg-mL-dexamethasone-sodium-phosphate-3062
43. Dexamethasone 3.3 mg/ml solution for injection - Summary of Product Characteristics (SmPC) - (emc) | 4659, accessed September 27, 2025, https://www.medicines.org.uk/emc/product/4659/smpc
44. Pharmacology Review(s) - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208742Orig1s000PharmR.pdf
45. Clinical Trials Using Dexamethasone - NCI, accessed September 27, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/dexamethasone?pn=1
46. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s027lbl.pdf
47. Dextenza (dexamethasone) FDA Approval History - Drugs.com, accessed September 27, 2025, https://www.drugs.com/history/dextenza.html
48. Dexamethasone Acetate‐Loaded PLGA Nanospheres Targeting Liver Macrophages - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11827543/
49. Dexamethasone acetate loaded poly(ε-caprolactone) nanofibers for rat corneal chemical burn treatment - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39300144/
50. Dexamethasone Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 27, 2025, https://www.drugs.com/dosage/dexamethasone.html
51. Maxidex dexamethasone ophthalmic) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 27, 2025, https://reference.medscape.com/drug/maxidex-dexamethasone-ophthalmic-343619
52. Dexamethasone Ophthalmic Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 27, 2025, https://www.drugs.com/dosage/dexamethasone-ophthalmic.html
53. Dexamethasone Injection: Uses & Side Effects - Cleveland Clinic, accessed September 27, 2025, https://my.clevelandclinic.org/health/drugs/20480-dexamethasone-injection
54. 7 Dexamethasone Interactions to Watch for - GoodRx, accessed September 27, 2025, https://www.goodrx.com/dexamethasone/interactions
55. Dexamethasone (Systemic: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed September 27, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/dexamethasone-systemic
56. Side effects of dexamethasone eye drops - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-eye-drops/side-effects-of-dexamethasone-eye-drops/
57. Dexamethasone Uses, Dosage & Side Effects - Drugs.com, accessed September 27, 2025, https://www.drugs.com/dexamethasone.html
58. Dexamethasone (oral route) - Side effects & dosage - Mayo Clinic, accessed September 27, 2025, https://www.mayoclinic.org/drugs-supplements/dexamethasone-oral-route/description/drg-20075207
59. Dexamethasone interactions: Alcohol, supplements, and more - Medical News Today, accessed September 27, 2025, https://www.medicalnewstoday.com/articles/drugs-dexamethasone-interactions
60. go.drugbank.com, accessed September 27, 2025, https://go.drugbank.com/drugs/DB14649#:~:text=The%20metabolism%20of%20Dexamethasone%20acetate%20can%20be%20decreased%20when%20combined%20with%20Amiodarone.&text=The%20metabolism%20of%20Amitriptyline%20can%20be%20increased%20when%20combined%20with%20Dexamethasone%20acetate.&text=Amphotericin%20B-,The%20risk%20or%20severity%20of%20hypokalemia%20can%20be%20increased%20when,is%20combined%20with%20Amphotericin%20B.
61. Corticosteroids for Common Palliative Care Symptoms, accessed September 27, 2025, https://www.mypcnow.org/fast-fact/corticosteroids-for-common-palliative-care-symptoms/
62. Study: Older Multiple Myeloma Patients can be Spared of Long-Term Steroids, accessed September 27, 2025, https://www.hematology.org/newsroom/press-releases/2021/study-older-multiple-myeloma-patients-can-be-spared-of-long-term-steroids
63. The effect of dexamethasone on the prevalence of delirium in older COVID-19 patients: a retrospective cohort study - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39969802/
64. What are the effects of dexamethasone (corticosteroid) in pregnancy? - Dr.Oracle AI, accessed September 27, 2025, https://droracle.ai/articles/101249/what-are-the-effects-of-dexamethasone-corticosteroid-in-pregnancy
65. Pregnancy, breastfeeding and fertility while taking dexamethasone tablets and liquid - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-tablets-and-liquid/pregnancy-breastfeeding-and-fertility-while-taking-dexamethasone-tablets-and-liquid/
66. Dexamethasone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501767/
67. Dexamethasone use while Breastfeeding - Drugs.com, accessed September 27, 2025, https://www.drugs.com/breastfeeding/dexamethasone.html
68. Dexamethasone, Topical - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 27, 2025, https://www.ncbi.nlm.nih.gov/sites/books/NBK501758/
69. Pregnancy, breastfeeding and fertility while using dexamethasone eye drops - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-eye-drops/pregnancy-breastfeeding-and-fertility-while-using-dexamethasone-eye-drops/
70. Dexamethasone Sodium Injection ANDA 084916 S066 - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/084916s066lbl.pdf
71. Determination That DECADRON-LA (Dexamethasone Acetate Injection), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed September 27, 2025, https://www.federalregister.gov/documents/2004/08/24/04-19287/determination-that-decadron-la-dexamethasone-acetate-injection-was-not-withdrawn-from-sale-for
72. Label: DEXAMETHASONE ACETATE ANHYDROUS powder - DailyMed, accessed September 27, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6bbb6a6-4c26-4de2-8277-c71bf5b6c81f
73. (Approval lapsed) DEXAMETHASONE MYLAN dexamethasone phosphate (as dexamethasone sodium phosphate) 4mg/1mL (Mylan USA) | Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/resources/section-19a-approvals/approval-lapsed-dexamethasone-mylan-dexamethasone-phosphate-dexamethasone-sodium-phosphate-4mg1ml-mylan-usa
74. Australian Public Assessment Report for Dexamethasone - Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/sites/default/files/auspar-dexamethasone-161025.pdf
75. Dexamethasone Viatris - NPS MedicineWise, accessed September 27, 2025, https://www.nps.org.au/medicine-finder/dexamethasone-mylan-injection-solution-for-injection
76. Dexamethasone Medsurge - NPS MedicineWise, accessed September 27, 2025, https://www.nps.org.au/medicine-finder/dexamethasone-medsurge
77. Dexmethsone - Healthdirect, accessed September 27, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,2956011000036100/dexmethsone
78. Dexamethasone Acetate - The University of Maryland, Baltimore, accessed September 27, 2025, https://archive.hshsl.umaryland.edu/bitstreams/3abc022e-67dd-4a79-bc06-8fd12ecb4dbe/download
79. Dexamethasone - Drug Usage Statistics, ClinCalc DrugStats Database, accessed September 27, 2025, https://clincalc.com/DrugStats/Drugs/Dexamethasone
80. DEXAMETHASONE - Pharmaceutical Benefits Scheme (PBS), accessed September 27, 2025, https://www.pbs.gov.au/medicine/item/1292b-2507y
81. Dexamethasone tablets and liquid: a steroid medicine - NHS, accessed September 27, 2025, https://www.nhs.uk/medicines/dexamethasone-tablets-and-liquid/
82. Generic DEXAMETHASONE INN equivalents, pharmaceutical patent and freedom to operate, accessed September 27, 2025, https://www.drugpatentwatch.com/p/generic/DEXAMETHASONE